Atjaunināt sīkdatņu piekrišanu

STAT Inhibitors in Cancer Softcover reprint of the original 1st ed. 2016 [Mīkstie vāki]

Edited by
  • Formāts: Paperback / softback, 195 pages, height x width: 235x155 mm, weight: 454 g, 11 Illustrations, color; VII, 195 p. 11 illus. in color., 1 Paperback / softback
  • Sērija : Cancer Drug Discovery and Development
  • Izdošanas datums: 16-Jun-2018
  • Izdevniecība: Birkhauser Verlag AG
  • ISBN-10: 3319827014
  • ISBN-13: 9783319827018
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 136,16 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 160,19 €
  • Ietaupiet 15%
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 195 pages, height x width: 235x155 mm, weight: 454 g, 11 Illustrations, color; VII, 195 p. 11 illus. in color., 1 Paperback / softback
  • Sērija : Cancer Drug Discovery and Development
  • Izdošanas datums: 16-Jun-2018
  • Izdevniecība: Birkhauser Verlag AG
  • ISBN-10: 3319827014
  • ISBN-13: 9783319827018
Citas grāmatas par šo tēmu:

This volume, which includes contributions from leading scientists and clinicians in the field, provides definitive, state-of-the-art information on STAT inhibitors in a biological and clinical context. It gives an overview of the biology of the STAT family of transcription factors and their role in cancer etiology. Additionally, it describes the raft of therapeutic approaches being used to inhibit STATs in the context of various cancers, covering the full spectrum of therapeutic approaches to inhibiting STATs, and presenting emerging data from clinical trials.

STATs in Health and Disease.- STAT Proteins in Cancer.- Translating STAT Inhibitors from the Lab to the Clinic.- Historical Development of STAT3 Inhibitors and Early Results in Clinical Trials.- STAT3 Inhibitors in Cancer: A Comprehensive Update.- Targeting Upstream Janus Kinases.- Inhibitors of Upstream Inducers of STAT Activation

Alister C. Ward is Foundation Professor/Director of Pre-Clinical Studies, School of Medicine, Deakin University, Geelong, Australia.